The contribution of the intestine to the nonlinear absorption of celiprolol in the rat was studied. After intravenous administration of 14C-celiprolol to bile duct-cannulated rats, approximately 9% of the dose was found to be associated with intestinal tissue and its contents. Microhistoautoradiography of frozen intestinal sections showed a time-dependent secretion of celiprolol from the blood into the lumen of the rat intestine. Propranolol, a lipophilic beta-blocker, was also found to be secreted into the intestine in vivo and transported in epithelial cells in both a temperature- and a pH-dependent manner, although to a lesser extent than celiprolol. Consistent with the observations in rats, transport of celiprolol from the basal-lateral to the apical side was found to dominate apical-to-basal transport using human Caco-2 cell monolayers. Additionally, using isolated rat small intestinal epithelial cells, celiprolol was found also to have a time- and temperature-dependent uptake, suggesting the involvement of a carrier-mediated system in its uptake. The uptake was inhibited by 2 mM celiprolol and propranolol and was also found to be pH dependent. Saturation of the carrier-mediated secretion of celiprolol in the intestine may result in enhanced absorption of celiprolol at high doses and account for its observed nonlinear absorption.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1018959809352 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Green Tea Catechins as Perpetrators of Drug Pharmacokinetic Interactions.
Clin Pharmacol Ther
January 2025
Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Green tea (Camellia sinensis) is a commonly consumed beverage or dietary supplement. As a natural product with a myriad of proposed health benefits, patients are likely to consume green tea while taking their medications unaware of its potential to interact with drugs and influence drug efficacy and safety. Catechins are the abundant polyphenolic compounds in green tea (e.
View Article and Find Full Text PDFPharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics.
Clin Transl Sci
February 2022
Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
The aim of this study was to search for associations of genetic variants with celiprolol pharmacokinetics in a large set of pharmacokinetic genes, and, more specifically, in a set of previously identified candidate genes ABCB1, SLCO1A2, and SLCO2B1. To this end, we determined celiprolol single-dose (200 mg) pharmacokinetics and sequenced 379 pharmacokinetic genes in 195 healthy volunteers. Analysis with 46,064 common sequence variants in the 379 genes did not identify any novel genes associated with celiprolol exposure.
View Article and Find Full Text PDFQuantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.
Br J Pharmacol
November 2021
Division of Genome and Cellular Functions, Department of Molecular and Cellular Biology, School of Life Science, Faculty of Medicine, Tottori University, Yonago, Japan.
Background And Purpose: P-glycoprotein (P-gp) exhibits a broad substrate specificity and affects pharmacokinetics, especially intestinal absorption. However, prediction, in vivo, of P-gp-mediated drug-drug interaction (DDI) and non-linear absorption at the preclinical stage, is challenging. Here we evaluate the use of human MDR1 mouse artificial chromosome (hMDR1-MAC) mice carrying human P-gp and lacking their own murine P-gp to quantitatively predict human P-gp-mediated DDI and non-linear absorption.
View Article and Find Full Text PDFIntestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings.
J Pharm Sci
September 2017
School of Pharmacy, University of Washington, Seattle, Washington 98195. Electronic address:
In recent years, an increasing number of clinical drug-drug interactions (DDIs) have been attributed to inhibition of intestinal organic anion-transporting polypeptides (OATPs); however, only a few of these DDI results were reflected in drug labels. This review aims to provide a thorough analysis of intestinal OATP-mediated pharmacokinetic-based DDIs, using both in vitro and clinical investigations, highlighting the main mechanistic findings and discussing their clinical relevance. On the basis of pharmacogenetic and clinical DDI results, a total of 12 drugs were identified as possible clinical substrates of OATP2B1 and OATP1A2.
View Article and Find Full Text PDFSmall-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.
J Pharm Sci
September 2017
Sugiyama Laboratory, RIKEN Innovation Center, Yokohama 2300045, Japan.
Article Synopsis
- The study aimed to explore how atorvastatin and grapefruit juice affect the pharmacokinetics of certain drugs that are processed by OATP2B1 and BCRP in healthy volunteers.
- Results indicated that grapefruit juice significantly decreased the absorption of the test drugs compared to a control phase, suggesting all five drugs are processed by OATP2B1, while atorvastatin did not have a similar effect.
- Genetic factors, specifically the ABCG2 c.421C>A polymorphism, influenced the levels of sulfasalazine and rosuvastatin absorbed, while the SLCO2B1*3 genotype did not affect the pharmacokinetics of any of the tested drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!